Phaseline

Companies › Prokrea BCN

Prokrea BCN: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PKB171
Phosphodiesterase inhibitor (pentoxifylline); increases sperm motility and peripheral bloo
PDEPhase 2Infertility Due to AzoospermiaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07669584PKB171Phase 2Infertility Due to AzoospermiaGenitourinaryOct 2027

Targets

PDE (1)

Companies with the same targets

–

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.